Health & Biotech ASX Health Stocks: Clarity Pharma says its drug could be effective in prostate cancer, shares jump 8pc November 30, 2023 Clarity Pharma says prostate cancer patient's PSA level dropped to undetectable levels following two cycles of 8GBq of 67Cu-SAR-bisPSMA. ‘Best place we’ve ever been’: AdAlta looks to monetise lead asset in 2024 November 30, 2023 After a decade of dedicated development on a leading asset AdAlta stands as a clinical-stage biopharmaceutical development company at a… On the rise: Erectile dysfunction nasal spray inventor LTR Pharma firms for ASX and major market disruption November 30, 2023 With a revolutionary erectile dysfunction nasal spray product in the works and an ASX listing in sight, LTR Pharma looks… Check Up: Imugene’s oncolytic virus VAXINIA granted FDA’s Fast Track, but how effective is this novel therapy? November 30, 2023 Imugene surges after oncolytic virus VAXINIA was given FDA's Fast Track designation. But could oncolytic virus really kill cancer cells? ASX Health Stocks: 4DX shares continue ascent after signing a deal with global player, Philips November 29, 2023 4DX jumps 10pc after signing a deal with global player, Philips. Fisher & Paykel also jumps after releasing H1 results. Dimerix gains on China drug application approval November 29, 2023 Dimerix was up 14% in morning trade after Chinese authorities approved an investigational new drug (IND) application to commence recruitment… Melodiol enjoys milestone 2023 as subsidiaries bank profits November 29, 2023 Cannabis play Melodiol Global Health is approaching the end of 2023 in a strong position delivering on its strategy to… Wellnex Life to rise 117pc in next 12 months forecasts Vested Equities November 28, 2023 Vested Equities has initiated coverage on Wellnex Life with an overweight rating and 11.5 cents/share 12-month price target, saying the… ‘Fundamentals for success in place’: Myriad drives growth as AROA reports strong first half November 28, 2023 Aroa Biosurgery released strong H1 FY24 results with top-line growth led by sales of its Myriad product family which grew… ASX Health Stocks: Nova Eye catches a break as US Medicare reimbursement decision deferred until March November 28, 2023 Nova Eye gets reprieve after US Medicare reimbursement delayed until 2024. Dimerix gets green light in China to start recruitment. Next» « Previous